Business
MetaStat Appoints Jerome B. Zeldis, M.D., Ph.D. to its Board of Directors
MetaStat Appoints Jerome B. Zeldis, M.D., Ph.D. to its Board of Directors.
About this update from Metastat Inc
[{"type":"text","content":"\n \n MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today \n announced the appointment of Jerome B. Zeldis, M.D., Ph.D. to serve as \n Vice Chairman of the company’s Board of Directors. Dr. Zeldis is the \n Chief Medical Officer of Celgene Corporation (NASDAQ: CELG) and Chief \n Executive Officer of Celgene Global Health.\n \n \n “We are delighted to have Dr. Zeldis join the MetaStat team,” said \n Douglas A. Hamilton, President and Chief Executive Officer, MetaStat, \n Inc. “I look forward to working with Jerry to broaden our diagnostic \n opportunities in oncology while monetizing our novel therapeutic assets, \n including potential drug candidates that target selected drivers of \n cancer metastasis.”\n \n \n Dr. Zeldis is the Chief Medical Officer of Celgene Corporation and Chief \n Executive Officer of Celgene Global Health. Prior to joining Celgene in \n 1997, Dr. Zeldis held positions at Sandoz Research Institute and Janssen \n Research Institute in both clinical research and medical development. He \n currently serves as Chairman of the board of Alliqua and Trek \n Therapeutics in addition to board positions at Bionor Pharma, PTC \n Therapeutics, and Soligenix. He was Assistant Professor of Medicine at \n Harvard Medical School, Associate Professor of Medicine at University of \n California, Davis, Clinical Associate Professor of Medicine at Cornell \n Medical School, and Professor of Clinical Medicine at the Robert Wood \n Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown \n University, and M Phil, MD, and PhD degrees from Yale University. Dr. \n Zeldis has published 121 peer-reviewed articles and 24 reviews, as well \n as a number of book chapters, and editorials.\n \n \n “MetaStat’s exciting technology based on the mechanisms that drive \n cancer metastasis, create the potential for next generation cancer \n diagnostics and an opportunity to develop novel cancer drugs in \n conjunction with strategic partners” stated Dr. Zeldis. “I look forward \n to helping expand development of MetaStat’s unique technology by \n creating new opportunities for these proprietary biomarkers for solid \n tumor metastasis.”\n \n \n About MetaStat, Inc.\n \n \n MetaStat develops and commercializes tissue-based diagnostic tests for \n pr...